Saturday, January 17, 2015

New E-approach to asthma: Automated Device for Asthma Monitoring and Management

ADAMM (Automated Device for Asthma Monitoring and Management) devices from Health Care Originals Inc. are displayed at the 2015 International CES at the Sands Expo and Convention Center on January 6, 2015 in Las Vegas, Nevada. The ADAMM is a wearable technology that automates asthma management and provides complete information for physicians.
http://healthcareoriginals.com/

By measuring vital signs and other biological readings, the ADAM will predict and log asthma attacks, and can recommend behavior changes as well. It's set to launch in the second quarter of this year, and the price has not yet been announced.
http://healthcareoriginals.com/

Friday, January 16, 2015

How Stop Smoking Changes Your Life



The grim news is that cigarette smoking is attributed to about 443,000 deaths each year in the United States. The good news is that the younger you are when you quit, the greater the health benefits. But quitting at any age can add years to your life. And some of the benefits are almost immediate. 

Sunday, January 4, 2015

The best 3 Respiratory apps released in 2014

1. Respi is a startup aiming to enable patients with asthma, COPD and other respiratory conditions. Respi is an comprehensive management system, comprised of a mobile spirometer and software that offers personalized advice to enable disease optimization by patients and their physicians.
http://respiratorydecade.blogspot.com/2014/11/respi-new-solution-for-copd-and-asthma.html

2. Amiko can help patients to become more mindful, more engaged, more active in managing their medication while we have also developed a bridge to keep the patients and the caregivers and their loved ones connected always. It also involves staying in touch with your personal doctor so he or she can stay updated on how the treatment is progressing, staying in touch with the pharmacists for automatic refill of your prescriptions.

http://respiratorydecade.blogspot.com/2014/11/amiko-new-smart-medication-management.html

3. Doctot GOLD COPD Strategy provides the GOLD strategy for assessing and treating COPD in a user-friendly and easily navigable format with interactive tables and charts. Physicians can easily record patient answers to questions about symptoms and functional status, and the app automatically generates and categorizes the patient's score on the Combined Assessment of COPD Scale. 
https://itunes.apple.com/us/app/gold-copd-strategy/id576193649?mt=8
 

Wednesday, December 24, 2014

Merry Christmas to all Respiratory friends

Merry Christmas to all Respiratory friends!!!
Thank you for all your permanent help and support in this hard year! We realized very useful things for promotion of ALL Respiratory conditions! We are hoping that we will continue this work with your help and in 2015!
 

Saturday, December 20, 2014

COPD and Asthma are remaining neglected at the global level

The forthcoming post-Millennium Development Goals era will bring about new challenges in global health. Low- and middle-income countries will have to contend with a dual burden of infectious and non-communicable diseases (NCDs). Some of these NCDs, such as neoplasms, COPD, cardiovascular diseases and diabetes, cause much health loss worldwide and are already widely recognized as doing so.
The chronic nature of asthma and COPD requires continuous care and reliable access to affordable medications. These conditions have been set out by the Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) together with the need to prevent exacerbations with the use, in the first instance, of inhaled drugs. However the costs and availability of inhaled drugs are very variable and there is a tendency for these to cost more in low income countries.

Saturday, December 13, 2014

European Commission must keep clean air on EU legislative agenda

Respiratory Decade is supporting Clean Air Package! 
In response to the increasing signs that the Junker Commission is going to withdraw the Clean Air Package from its 2015 Work Programme, the European Respiratory Society and European Lung Foundation (ELF), who are advocating for cleaner air as part of the Healthy Lungs for Life campaign, noted that:
"If the Junker Commission is looking for big problems to solve that will have a big impact on the health and well-being of the European population, air pollution is one of the most important as it affects 100% of us. By dropping the Clean Air Package and the National Emission Ceilings directive, Mr Timmermans is missing a prime opportunity – the NEC Directive would reduce exposure to pollutants in the air which currently cause 400,000 premature deaths in Europe each year. It would also testify to EU's leadership on green growth and environmental protection on the international stage, would act as a catalyst for energy policy targets and would encourage industry to innovate on their climate change action. Instead, the health concerns of Europeans have been dropped and our health will suffer".

Sunday, December 7, 2014

Do you have Obstructive Sleep Apnea?

Most individual symptoms and signs have limited utility in determining the likelihood of OSA, and no one sign is sufficiently precise to rule in or rule out this condition. Although the absence of snoring makes a diagnosis of OSA less likely, snoring on its own is common and does not discriminate between those with and without OSA. Thus, snoring must be interpreted in the context of other symptoms and signs. Likewise, self-reported sleepinessandmorning headaches do not help discriminate among patients with and without OSA. It is somewhat surprising that the overall impression of sleep medicine physicians of the likelihood of OSA in individual patients does not perform much better than the limited utility of individual findings. It is important to recognize that persons with normal body weight who do not snore are unlikely to have OSA, and their complaints of daytime sleepiness or fatigue should prompt an evaluation for alternative diagnoses. 

Although the evidence shows that a number of recently published multi-itemed questionnaires may help rule out OSA, they are not helpful in identifying patients affected by sleep apnea. Fortunately, it appears that an explicit combination of only a few findings, expressed as the SACS, has promise for identifying patients most likely to have OSA. Although the test is seemingly easy to use, validation at current diagnostic thresholds in more general populations by primary care clinicians would provide important evidence to justify its use in routine screening.